3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Gender: Female -

Osteoporosis drug may also normalize heart rate

Gender: FemaleMay 25, 06

Treatment with raloxifene appears to reduce heart rate variability in elderly women with osteoporosis, Turkish researchers report in the American Journal of Obstetrics and Gynecology.

There is some evidence that raloxifene, sold under the trade name Evista, may have a protective effect on women with cardiovascular disease or who have a high risk of developing cardiovascular disease, but the effects are still unclear, Dr. Mert Gol and colleagues at Dokuz Eylul University Hospital, Izmir, note.

The researchers therefore studied 43 postmenopausal women with osteoporosis. The women were randomly assigned to raloxifene at 60 mg daily or another drug that prevents or slows down osteoporosis—alendronate (trade name Fosamax) at 10 mg daily.

At as early as three months, the researchers found that raloxifene decreased hyperactivity in the sympathetic nervous system, which is associated with cardiovascular disease, and this persisted until the end of treatment at six months.

Also, measurement of the average intervals between heartbeats, a sensitive indication of parasympathetic nervous system activity, tended to increase in the raloxifene group, with suggests reduced sympathetic activity.

Because activation of the sympathetic nervous system is associated with cardiovascular disease, the team concludes that raloxifene treatment may have a positive effect on cardiovascular health in these women.”

The investigators note that a trial to evaluate these effects is currently underway.

SOURCE: American Journal Obstetrics Gynecology, May 2006.



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  What’s the life expectancy of patients when they begin treatment for osteoporosis?
  Addressing the needs of young women with disorders of sex development
  Study ties breathing problems, asthma to bone loss
  Arkansas to appeal ruling on abortion restriction law
  Supreme Court declines to hear new contraception cases
  Optimism linked to healthier eating among women
  Lactation consultants can boost breastfeeding
  Sexual function dramatically improves in women following bariatric surgery, Penn study finds
  Arkansas governor vetoes bill banning abortions at 20 weeks
  In Vitro Fertilization Less Successful With Alternative Fertility Treatments
  House GOP look to reshape birth control debate
  Online dating research shows cupid’s arrow is turning digital

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site